Non-coding RNA-mediated endothelial-to-mesenchymal transition in human diabetic cardiomyopathy, potential regulation by DNA methylation
Authors' conclusion
We show that EndMT is a relevant pathological process in human hearts during DCM, and that its occurrence coincides with changes in relevant ncRNAs. We further find that interplay between DNA methylation and certain ncRNAs involved in the regulation of EndMT may contribute to the observed changes in ncRNA expression. These findings reinforce the role of EndMT in patients afflicted with DCM and underscore the complexities and importance of the interactions between different facets of epigenetic regulation.
Study context
- Population
- Autopsy patients; formalin-fixed, paraffin-embedded heart tissue
- Comparison
- Diabetic vs non-diabetic autopsy hearts
- Outcome
- EndMT and ncRNAs in human diabetic cardiomyopathy (DCM)
Methodological detailsautopsy heart tissue, histology and immunofluorescence, RT-qPCR, methylation analysis
- Autopsy heart tissue
- Histology and immunofluorescence
- RT-qPCR
- Methylation analysis
Main finding
As reported in the abstract
- Diabetic patients showed increased cardiac fibrosis; Endothelial-to-mesenchymal transition (EndMT) had occurred (histology, immunofluorescence)
- RT-qPCR: EndMT occurs in diabetic hearts and corresponds to changes in key non-coding RNAs (ncRNAs)
- Some EndMT-related ncRNAs regulated by DNA promoter methylation; others may be regulated by different epigenetic mechanisms
Original publication
Non-coding RNA-mediated endothelial-to-mesenchymal transition in human diabetic cardiomyopathy, potential regulation by DNA methylation. Cardiovasc Diabetol. Published 3 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →